Forecast

The analysts' average price target is +29,68€ (+41,27%). The median is +29,20€ (+38,98%).

Buy	19
Hold	0
Sell	0

News Go to news feed

Denali stock falls after failed phase-2b Parkinson study

Denali shares fell after it was announced that the phase-2b LUMA study of the LRRK2 inhibitor BIIB122 (DNL151), developed with Biogen, failed to meet primary or secondary endpoints. The drug showed peripheral kinase inhibition >90% and reduced a biomarker in cerebrospinal fluid but produced no clinical benefit; BIIB122 will not be pursued for the treatment of idiopathic Parkinson’s. Denali will continue the independent phase-2a BEACON study in carriers of pathogenic LRRK2 variants; data are expected in H1 2027. In premarket trading, Denali stock dropped about 2.9% and Biogen about 1%. » More on de.investing.com
Denali regains full control of DNL593 after Takeda ends collaboration

Takeda terminated the collaboration on DNL593 for strategic reasons unrelated to the drug’s efficacy or safety, returning full development and IP control to Denali. Denali says the TransportVehicle technology remains a promising approach for neurodegeneration and will present Phase I/II findings for DNL593 by the end of 2026. Management views sole ownership of DNL593 as positive for future development. » More on finance.yahoo.com
Denali Therapeutics receives $200 million after accelerated FDA approval

Denali Therapeutics received $200 million in gross proceeds from a synthetic royalty financing with Royalty Pharma; the payment was triggered by the accelerated FDA approval of Tividenofusp Alfa (Avlayah) on March 24 and the transaction closed on March 27. The company gave no further details on contract terms or planned use of the funds. Avlayah’s approval for treating neurological manifestations of Hunter syndrome was based on a median reduction of cerebrospinal fluid heparan sulfate concentration by 91% at week 24, with 93% of patients reaching normal levels. Following the milestone, several research houses raised their price targets for Denali but kept their ratings unchanged. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Denali Therapeutics has already paid 0,28€ in dividends. The last payout was in April 2022.

Financials

In the last quarter, Denali Therapeutics had revenue of 3,16 Mio€ and net profit of −111,76 Mio€

(EUR)	Jun 2026	YoY
Revenue	+3,16 Mio	-
Gross profit	+3,08 Mio	-
Net profit	−111,76 Mio	6,13%
EBITDA	−108,64 Mio	6,56%

Fundamentals

Metric	Value
Market capitalization	+3,40 Mrd€
Number of shares	158,71 Mio
52-week high/low	+23,44€ - +10,80€
Dividends	No
Beta	1
P/E ratio	−8,78
PEG ratio	+5,13
P/B ratio	+5,59
P/S ratio	+1.097,85

Company profile

Denali Therapeutics Inc. ist ein biopharmazeutisches Unternehmen, das in den Vereinigten Staaten therapeutische Kandidaten für neurodegenerative Krankheiten entdeckt und entwickelt. Es bietet Produktkandidaten zur Hemmung der Leucin-reichen Repeat-Kinase 2 (LRRK2) an, darunter BIIB122/DNL151, einen niedermolekularen Hemmstoff, der sich in klinischen Studien der Phasen I und Ib zur Behandlung der Parkinson-Krankheit befindet. Das Unternehmen entwickelt auch DNL310, das sich in klinischen Studien der Phase I/II zur Behandlung des Hunter-Syndroms befindet; DNL343, das sich in einer klinischen Studie der Phase 1 zur Behandlung der amyotrophen Lateralsklerose (ALS) befindet; AR443820/DNL788, das eine klinische Studie der Phase I zur Behandlung von ALS, Multipler Sklerose (MS) und der Alzheimer-Krankheit abgeschlossen hat; und SAR443122/DNL758, das sich in einer klinischen Studie der Phase II zur Behandlung des kutanen Lupus erythematodes befindet. Das Unternehmen hat Kooperationsvereinbarungen mit Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, der Michael J. Fox Foundation und Centogene sowie eine Forschungs- und Optionsvereinbarung mit Secarna Pharmaceuticals GmbH & Co. KG zur Entwicklung von Antisense-Therapien auf dem Gebiet der neurodegenerativen Erkrankungen. Das Unternehmen war früher als SPR Pharma Inc. bekannt und änderte im März 2015 seinen Namen in Denali Therapeutics Inc. um. Denali Therapeutics Inc. wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.

Name	Denali Therapeutics
CEO	Ryan J. Watts
Headquarters	South San Francisco, ca USA
Website	denalitherapeutics.com
Sector	Consumer Staples
Industry	Food Products
IPO	12/08/2017
Employees	503